Novavax, Inc. (FRA:NVV1)

Market Cap	935.14M
Revenue (ttm)	907.40M
Net Income (ttm)	291.27M
Shares Out	n/a
EPS (ttm)	1.76
PE Ratio	3.21
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,671
Average Volume	2,950
Open	6.04
Previous Close	6.02
Day's Range	5.81 - 6.04
52-Week Range	4.56 - 11.23
Beta	n/a
RSI	45.76
Earnings Date	Feb 26, 2026

About Novavax

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 952
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: NVV1

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Financial numbers in USD